Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

NCT04950764 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04950764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04950764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Completed
Start date
November 16, 2021
Completion date
February 27, 2025
Enrollment
24 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

compensated cirrhosis, hepatic impairment, primary biliary cholangitis